MacroGenics, Inc. cash flow to debt ratio of -75.91% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

MacroGenics, Inc.'s free cash flow has decreased 15.09% from $-72.08M last year to $-82.95M, signaling decreasing performance

MacroGenics, Inc.'s debt to equity ratio is 1.72, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

MacroGenics, Inc.'s debt has increased relative to shareholder equity from 0.32 last year to 1.72 today, signaling weakened financials

MacroGenics, Inc. has negative EBITDA, making leverage ratio unreliable

MacroGenics, Inc.'s interest coverage ratio is -4.78, which means that the company struggles to meet interest obligations, signaling financial risk.

MacroGenics, Inc.'s profit margin has increased (-0.78%) in the last year from -45.14% to -44.79%, signaling increasing performance

MacroGenics, Inc.'s short-term assets of $219.94M exceed its short-term liabilities of $43.12M

MacroGenics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

MacroGenics, Inc.'s return on equity of -147.80%, is lower than 15.00%, indicating bad performance

MacroGenics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

MacroGenics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

MacroGenics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

MacroGenics, Inc. has negative free cash flow, indicating cash burn

MacroGenics, Inc.'s yearly earnings has decreased 11.43% since last year from $-66.97M to $-74.62M, signaling decreasing performance

MacroGenics, Inc.'s yearly revenue has increased 0.78% since last year from $148.34M to $149.50M, signaling increasing performance

ROIC -49.59% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

MacroGenics, Inc.'s 3-year revenue CAGR of -0.12% is negative, indicating declining revenue over the past 3 years

MacroGenics, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

MacroGenics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

MacroGenics, Inc. has insufficient data to evaluate this check.

MacroGenics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

MacroGenics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

MacroGenics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

MacroGenics, Inc. is overvalued relative to its fair value price of -37.08 based on Earnings Fair Value model

MacroGenics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

MacroGenics, Inc. has a price-to-book ratio of 12.84x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

MacroGenics, Inc. has a price-to-sales ratio of 1.73x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue